Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

West Financial Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, ...

As that figure was large, weight loss drug producer Eli Lilly (NYSE: LLY) saw a nearly 2% bump in its share price in response ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.